Literature DB >> 17105868

Concurrent administration of Neu2000 and lithium produces marked improvement of motor neuron survival, motor function, and mortality in a mouse model of amyotrophic lateral sclerosis.

Jin Hee Shin1, Sung Ig Cho, Hyang Ran Lim, Jae Keun Lee, Young Ae Lee, Jai Sung Noh, In Soo Joo, Kee-Won Kim, Byoung Joo Gwag.   

Abstract

The Fas pathway and oxidative stress mediate neuronal death in stroke and may contribute to neurodegenerative disease. We tested the hypothesis that these two factors synergistically produce spinal motor neuron degeneration in amyotrophic lateral sclerosis (ALS). Levels of reactive oxygen species were increased in motor neurons from ALS mice compared with wild-type mice at age 10 weeks, before symptom onset. The proapoptotic proteins Fas, Fas-associated death domain, caspase 8, and caspase 3 were also elevated. Oral administration of 2-hydroxy-5-(2,3,5,6-tetrafluoro-4-trifluoromethyl-benzylamino)-benzoic acid (Neu2000), a potent antioxidant, blocked the increase in reactive oxygen species but only slightly reduced activation of proapoptotic proteins. Administration of lithium carbonate (Li(+)), a mood stabilizer that prevents apoptosis, blocked the apoptosis machinery without preventing oxidative stress. Neu2000 or Li(+) alone significantly enhanced survival time and motor function and together had an additive effect. These findings provide evidence that jointly targeting oxidative stress and Fas-mediated apoptosis can prevent neuronal loss and motor dysfunction in ALS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17105868     DOI: 10.1124/mol.106.030676

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  23 in total

1.  Safety and efficacy of lithium in combination with riluzole for treatment of amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.

Authors:  Swati P Aggarwal; Lorne Zinman; Elizabeth Simpson; Jane McKinley; Katherine E Jackson; Hanika Pinto; Petra Kaufman; Robin A Conwit; David Schoenfeld; Jeremy Shefner; Merit Cudkowicz
Journal:  Lancet Neurol       Date:  2010-04-01       Impact factor: 44.182

Review 2.  Neuroprotective action of lithium in disorders of the central nervous system.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Zhong Nan Da Xue Xue Bao Yi Xue Ban       Date:  2011-06

Review 3.  Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders.

Authors:  Chi-Tso Chiu; De-Maw Chuang
Journal:  Pharmacol Ther       Date:  2010-08-10       Impact factor: 12.310

4.  Impact of lithium alone or in combination with haloperidol on selected oxidative stress parameters in human plasma in vitro.

Authors:  Oliwia Gawlik-Kotelnicka; Wojciech Mielicki; Jolanta Rabe-Jabłońska; Dominik Strzelecki
Journal:  Redox Rep       Date:  2016-03-08       Impact factor: 4.412

5.  MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS.

Authors:  Jae Keun Lee; Jin Hee Shin; Sang Gil Hwang; Byoung Joo Gwag; Ann C McKee; Junghee Lee; Neil W Kowall; Hoon Ryu; Dae-Sik Lim; Eui-Ju Choi
Journal:  Proc Natl Acad Sci U S A       Date:  2013-07-01       Impact factor: 11.205

Review 6.  Signaling by death receptors in the nervous system.

Authors:  Georg Haase; Brigitte Pettmann; Cédric Raoul; Christopher E Henderson
Journal:  Curr Opin Neurobiol       Date:  2008-06       Impact factor: 6.627

7.  Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model.

Authors:  H-L Feng; Y Leng; C-H Ma; J Zhang; M Ren; D-M Chuang
Journal:  Neuroscience       Date:  2008-06-21       Impact factor: 3.590

Review 8.  Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder.

Authors:  Chi-Tso Chiu; Zhifei Wang; Joshua G Hunsberger; De-Maw Chuang
Journal:  Pharmacol Rev       Date:  2013-01-08       Impact factor: 25.468

9.  Lithium delays progression of amyotrophic lateral sclerosis.

Authors:  Francesco Fornai; Patrizia Longone; Luisa Cafaro; Olga Kastsiuchenka; Michela Ferrucci; Maria Laura Manca; Gloria Lazzeri; Alida Spalloni; Natascia Bellio; Paola Lenzi; Nicola Modugno; Gabriele Siciliano; Ciro Isidoro; Luigi Murri; Stefano Ruggieri; Antonio Paparelli
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-04       Impact factor: 11.205

10.  No benefit from chronic lithium dosing in a sibling-matched, gender balanced, investigator-blinded trial using a standard mouse model of familial ALS.

Authors:  Alan Gill; Joshua Kidd; Fernando Vieira; Kenneth Thompson; Steven Perrin
Journal:  PLoS One       Date:  2009-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.